Search results for "HEREDITARY"

showing 10 items of 650 documents

The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN

2022

Primary ciliary dyskinesia; Rare genetic disorder; Lung diseases Discinesia ciliar primaria; Trastorno genético raro; Enfermedades pulmonares Discinesia ciliar primària; Trastorn genètic rar; Malalties pulmonars Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterised by impaired mucociliary clearance leading to irreversible lung damage. In contrast to other rare lung diseases like cystic fibrosis (CF), there are only few clinical trials and limited evidence-based treatments. Management is mainly based on expert opinions and treatment is challenging due to a wide range of clinical manifestations and disease severity. To improve clinical and translational research and facili…

Pulmonary and Respiratory Medicine:enfermedades respiratorias::trastornos de la motilidad ciliar [ENFERMEDADES]:Health Occupations::Medicine::Pediatrics [DISCIPLINES AND OCCUPATIONS]Respiratory SystemSağlık BilimleriClinical Medicine (MED)SOLUNUM SİSTEMİRespiratory CareHealth SciencesMANAGEMENTKlinik Tıp (MED)Chest Diseases and Allergy:profesiones sanitarias::medicina::pediatría [DISCIPLINAS Y OCUPACIONES]:Otros calificadores::/terapia [Otros calificadores]:Respiratory Tract Diseases::Ciliary Motility Disorders [DISEASES]Internal Medicine SciencesScience & TechnologyKlinik TıpMUTATIONSRESPIRATORY SYSTEM:Other subheadings::/therapy [Other subheadings]Dahili Tıp BilimleriGöğüs Hastalıkları ve AllerjiCLINICAL MEDICINECèl·lules - Motilitat:Congenital Hereditary and Neonatal Diseases and Abnormalities::Genetic Diseases Inborn [DISEASES]TıpPulmons - Malalties - TractamentAkciğer ve Solunum TıbbıMedicineMalalties congènites:enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas [ENFERMEDADES]Solunum BakımıLife Sciences & BiomedicinePulmons Malalties
researchProduct

Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review.

2013

Hereditary angioedema (HAE) due to C1 esterase inhibitor (HAE-C1-INH) deficiency is a rare genetic disorder presenting with recurrent episodes of skin swellings, abdominal pain attacks, and potentially fatal laryngeal edema. This study was designed to review the efficacy and safety of pasteurized, human, plasma-derived C1-INH concentrate for the treatment of patients with HAE-C1-INH. A systematic search of electronic databases up to December 2011 was performed without language or date restrictions. Two reviewers completed the study selection using predefined inclusion criteria, tabulated, and analyzed the data. The data were inappropriate for meta-analysis; thus, a qualitative synthesis was…

Pulmonary and Respiratory MedicineAdultMaleAbdominal painmedicine.medical_specialtyAdolescentPlacebolaw.inventionYoung AdultQuality of lifeRandomized controlled triallawInternal medicineImmunology and AllergyMedicineHumansYoung adultChildRandomized Controlled Trials as TopicHereditary Angioedema Types I and IIbusiness.industryGeneral Medicinebacterial infections and mycosesmedicine.diseaseSystematic reviewTreatment OutcomeChild PreschoolHereditary angioedemaObservational studyFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinAllergy and asthma proceedings
researchProduct

Blindness, tetraspasticity, and other signs of irreversible brain damage in hereditary angioedema

2017

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentImmunologyBrain damageLaryngeal EdemaBlindness03 medical and health sciences0302 clinical medicinemedicineImmunology and AllergyHumans030212 general & internal medicineHypoxia BrainBlindnessHereditary Angioedema Types I and IIbusiness.industryLaryngeal Edemamedicine.diseaseDermatologyMuscle SpasticityHereditary angioedemamedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Efficacy of C1 esterase inhibitor concentrate in treatment of cutaneous attacks of hereditary angioedema.

2015

BACKGROUND Although treatment with C1 esterase inhibitor (C1-INH) concentrate is well established for hereditary angioedema (HAE) attacks in general, data that assess its efficacy for cutaneous attack treatment are sparse. OBJECTIVE To assess efficacy of plasma-derived, nanofiltered C1-INH concentrate for cutaneous attack treatment by comparing treated attacks from the uncontrolled I.M.P.A.C.T.2 study with historical data for untreated attacks. METHODS Cutaneous attack data from patients with HAE who were treated for cutaneous edema with 20 IU/kg body weight C1-INH concentrate in the uncontrolled I.M.P.A.C.T.2 study (38 patients) were compared with data from untreated patients from an histo…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentUntreated groupPeripheral edemaGastroenterologySeverity of Illness IndexYoung AdultInternal medicineSeverity of illnessmedicineImmunology and AllergyHumansYoung adultChildAgedEnd pointbusiness.industryAngioedemas HereditaryGeneral MedicineArticlesMiddle Agedmedicine.diseasePeripheralC1 esteraseTreatment OutcomeHereditary angioedemaDisease ProgressionFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinAllergy and asthma proceedings
researchProduct

Economic costs associated with acute attacks and long-term management of hereditary angioedema.

2010

Background Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent acute attacks of swelling of the larynx, abdomen, and periphery. Objective To assess the economic burden associated with acute attacks and long-term management of HAE. Methods Burden was assessed via a Web-based survey of HAE patients (≥18 years old) that solicited information on attack characterization, short-term treatment, long-term disease management, impact on work, and patient costs. A standardized instrument, the Work Productivity and Activity Impairment questionnaire, was included to assess impact on work productivity. Standard medical costs and US average wage costs were assigned…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyEmergency Medical Servicesmedia_common.quotation_subjectImmunologyWageDrug CostsIndirect costsCost of IllnessEconomic costSurveys and QuestionnairesLong term managementmedicineImmunology and AllergyHumansDisease management (health)Hospital CostsProductivityhealth care economics and organizationsmedia_commonbusiness.industryAngioedemas HereditaryEmergency departmentHealth Care Costsmedicine.diseaseHospitalizationHealth Care SurveysEmergency medicineHereditary angioedemaAcute DiseasePhysical therapyFemalebusinessAnnals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology
researchProduct

Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, a…

2008

Background We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) in 2004. Objective To ensure that this consensus remains current. Methods In collaboration with the Canadian Network of Rare Blood Disorder Organizations, we held the second Canadian Consensus discussion with our international colleagues in Toronto, Ontario, on February 3, 2006, and reviewed its content at the Fifth C1 Inhibitor Deficiency Workshop in Budapest on June 2, 2007. Papers were presented by international investigators, and this consensus algorithm approach resulted. Results This consensus algorithm …

Pulmonary and Respiratory MedicineConsensus algorithmmedicine.medical_specialtyCanadaC1 inhibitor deficiencyConsensus Development Conferences as TopicInternational CooperationImmunologyMEDLINEEcallantidemedicineImmunology and AllergyHumansHungarybusiness.industryAngioedemas HereditaryState of the art reviewEvidence-based medicinemedicine.diseaseBlood DisorderFamily medicineHereditary angioedemaControlled Clinical Trials as TopicbusinessAlgorithmsmedicine.drugAnnals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology
researchProduct

Pulmonary microvascular architecture in hereditary haemorrhagic telangiectasia

2017

A 24-year-old Caucasian man was admitted with a known hereditary haemorrhagic telangiectasia (HHT) and heterozygous mutation of factor V Leiden following episodes of cerebral infarctions in occipital lobes, cerebellum and brainstem. In his case history, the patient underwent several interventional embolisation of arteriovenous (AV) malformations in the middle and lower lobes (figure 1). However, those were not completely successful as the malformations were diffuse. We performed video-assisted thoracoscopic surgery with a resection of the middle lobe and a wedge resection of segment 10. Figure 1 CT scans depict the pulmonary arteriovenous malformations after re-embolisation in the middle lo…

Pulmonary and Respiratory MedicineMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyMucocutaneous zoneMedizinArticleResection03 medical and health sciencesYoung Adult0302 clinical medicineMicroscopy Electron Transmissionhemic and lymphatic diseasesotorhinolaryngologic diseasesmedicineFactor V LeidenHumans030223 otorhinolaryngologyLungHeterozygous mutationHereditary haemorrhagic telangiectasiabusiness.industryMiddle LobeMicrovascular architecturemedicine.diseaseSurgery030228 respiratory systemMicrovesselsTelangiectasia Hereditary HemorrhagicRadiologybusinessTomography X-Ray ComputedWedge resection (lung)
researchProduct

Shedding some light on tricuspid intervention

2021

Background More than 1.6 million Americans have at least moderate to severe valvular tricuspid regurgitation, yet fewer than 8000 tricuspid valve operations are performed annually in the USA. The undertreatment for isolated tricuspid regurgitation might be related to the fact that in the past years no clear guidelines on 'how' and 'when' to treat tricuspid regurgitation were issued. Aims Sarris-Michopoulos and colleagues carried out a meta-analysis with the aim to investigate the role of tricuspid valve repair versus tricuspid valve replacement in patients with isolated tricuspid valve regurgitation. Material and methods Outcomes of patients with first-time surgery for isolated tricuspid va…

Pulmonary and Respiratory MedicineModerate to severecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPercutaneousContext (language use)Regurgitation (circulation)Intervention (counseling)Internal medicineHumansMedicinecardiovascular diseasesRetrospective StudiesHeart Valve Prosthesis ImplantationTricuspid valvebusiness.industryTricuspid Valve InsufficiencySurgeryTreatment Outcomemedicine.anatomical_structureVentricleCohortcardiovascular systemCardiologySurgeryTricuspid ValveTricuspid Valve RegurgitationCardiology and Cardiovascular Medicinebusiness
researchProduct

THE STATE OF FRACTIONAL HEREDITARY MATERIALS (FHM)

2014

The widespread interest on the hereditary behavior of biological and bioinspired materials motivates deeper studies on their macroscopic ``minimal" state. The resulting integral equations for the detected relaxation and creep power-laws, of exponent $\beta$, are characterized by fractional operators. Here strains in $SBV_{loc}$ are considered to account for time-like jumps. Consistently, starting from stresses in $L_{loc}^{r}$, $r\in [1,\beta^{-1}], \, \, \beta\in(0,1)$ we reconstruct the corresponding strain by extending a result in [42]. The ``minimal" state is explored by showing that different histories delivering the same response are such that the fractional derivative of their differ…

Pure mathematicsState variableApplied MathematicsZero (complex analysis)State (functional analysis)Integral equationAction (physics)Fractional calculusFractional hereditary materials power-law functionally graded microstructureExponentDiscrete Mathematics and CombinatoricsRelaxation (physics)Settore ICAR/08 - Scienza Delle CostruzioniMathematics
researchProduct

Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study…

2020

BACKGROUND: Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled into a randomised trial of daily aspirin versus placebo. This report completes the planned 10-year follow-up to allow a longer-term assessment of the effect of taking regular aspirin in this high-risk population.METHODS: In the double-blind, randomised CAPP2 trial, 861 patients from 43 international centres worldwide (707 [82%] from Europe, 112 [13%] from Australasia, 38 [4%] from Africa, and four [&l…

RESISTANT STARCHPlacebo-controlled study030204 cardiovascular system & hematology0302 clinical medicineLife Tables030212 general & internal medicine11 Medical and Health Sciencesmedia_commonRISKAspirineducation.field_of_studyAnti-Inflammatory Agents Non-SteroidalLOW-DOSE ASPIRINGeneral MedicineLynch syndrome3. Good healthIntention to Treat AnalysisAnti-Inflammatory Agents Non-Steroidal/adverse effectsmedicine.drugCHEMOPREVENTIONmedicine.medical_specialtyHeterozygote3122 CancersPopulationNEOPLASIAAspirin/adverse effectsPlaceboCAPP2 InvestigatorsMedication Adherence03 medical and health sciencesDouble-Blind MethodInternal medicineGeneral & Internal MedicineColorectal Neoplasms Hereditary Nonpolyposis/geneticsBENEFITSmedicinemedia_common.cataloged_instanceHumansEuropean unioneducationProportional Hazards ModelsIntention-to-treat analysisCancer preventionAspirinbusiness.industryMORTALITY3126 Surgery anesthesiology intensive care radiologymedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisbusinessFollow-Up Studies
researchProduct